Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00135811 · ClinicalTrials.gov registry record · Phase 3
Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT)
A Phase 3 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 3
- Development phase
- 207
- Enrollment target
NCT00135811: Completed Phase 3 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
NCT00135811 is a Phase 3 study that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 207 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00135811, a Phase 3 study, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 207 participants
- Enrollment target
Study Summary
The FSGS Clinical Trial is a multi-center, prospective, controlled, open label randomized trial designed to determine if treatment with mycophenolate mofetil (MMF) in conjunction with pulse steroids is superior to treatment with Cyclosporine-A (CSA) in inducing remission from proteinuria over 12 months.
Interventions
- DRUG Cyclosporin
- DRUG MMF and Dexamethasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 207 participants |
| Start Date | 2004-11 |
| Est. Completion | 2009-10 |
| Phase | Phase 3 |
What the finished NCT00135811 record still lists
NCT00135811 is an interventional study that assigns participants to a tested intervention. The registered 207 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 2 interventions - of which Cyclosporin is the first listed.
NCT00135811 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00135811 about?
NCT00135811 is a clinical study titled "Focal Segmental Glomerulosclerosis Clinical Trial (FSGS-CT)". The FSGS Clinical Trial is a multi-center, prospective, controlled, open label randomized trial designed to determine if treatment with mycophenolate mofetil (MMF) in conjunction with pulse steroids is superior to treatment with Cyclosporine-A (CSA) in inducing remission from proteinuria over 12 mon...
What is the current status of trial NCT00135811?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 207 participants. The study started on 2004-11. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00135811?
The interventions under investigation include: Cyclosporin (DRUG), MMF and Dexamethasone (DRUG).
Who is sponsoring clinical trial NCT00135811?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00135811's enrollment target sits among peer trials
207 1346th of 2000 higher than 654 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04353778 · 207 participants · Phase 1
Effects of Vagal Dysfunction on Gastrointestinal and Inflammatory Pathways in HIV
- NCT05875805 · 207 participants · NA
A Telehealth Advance Care Planning Intervention
- NCT06254950 · 207 participants · Phase 2
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
- NCT06904274 · 207 participants · Phase 3
Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia